Dantrolene--a review of its pharmacology, therapeutic use and new developments.
about
Arthrogryposis: a review and updateGPR55 is a cannabinoid receptor that increases intracellular calcium and inhibits M currentClinical review: Treatment of heat stroke: should dantrolene be considered?Recovery of neuronal and network excitability after spinal cord injury and implications for spasticityPharmGKB summary: very important pharmacogene information for RYR1Antiarrhythmic Effects of Dantrolene in Patients with Catecholaminergic Polymorphic Ventricular Tachycardia and Replication of the Responses Using iPSC ModelsUpregulation of the CaV 1.1-ryanodine receptor complex in a rat model of critical illness myopathyDeranged calcium signaling and neurodegeneration in spinocerebellar ataxia type 3Ascorbic Acid as an Initiator for the Direct CH Arylation of (Hetero)arenes with Anilines Nitrosated In SituThe role of ryanodine receptor type 3 in a mouse model of Alzheimer diseaseLong-term dantrolene treatment reduced intraneuronal amyloid in aged Alzheimer triple transgenic miceCalcium dynamics regulating the timing of decision-making in C. elegans.Levamisole and ryanodine receptors. I: A contraction study in Ascaris suumCalcium Dynamics Mediated by the Endoplasmic/Sarcoplasmic Reticulum and Related Diseases.Ryanodine receptor channelopathies.Pharmacokinetic evaluation of oral dantrolene in the dog.Dantrolene mitigates caerulein-induced pancreatitis in vivo in mice.Role of presenilins in neuronal calcium homeostasisThe ryanodine receptor mediates early zymogen activation in pancreatitis.Excited deliriumMalignant hyperthermia susceptibility arising from altered resting coupling between the skeletal muscle L-type Ca2+ channel and the type 1 ryanodine receptorComputational analysis of calcium signaling and membrane electrophysiology in cerebellar Purkinje neurons associated with ataxia.Altered Ca(2+) signaling in skeletal muscle fibers of the R6/2 mouse, a model of Huntington's diseaseA calcium-dependent protease as a potential therapeutic target for Wolfram syndromeEffects of azumolene on normal and malignant hyperthermia-susceptible skeletal muscle.Localization of the dantrolene-binding sequence near the FK506-binding protein-binding site in the three-dimensional structure of the ryanodine receptor.Special article: Future directions in malignant hyperthermia research and patient careDantrolene is neuroprotective in Huntington's disease transgenic mouse model.The couplonopathies: A comparative approach to a class of diseases of skeletal and cardiac muscle.Oxidation of ryanodine receptor (RyR) and calmodulin enhance Ca release and pathologically alter, RyR structure and calmodulin affinity.Reactive oxygen species scavenger N-acetyl cysteine reduces methamphetamine-induced hyperthermia without affecting motor activity in mice.Dantrolene rescues arrhythmogenic RYR2 defect in a patient-specific stem cell model of catecholaminergic polymorphic ventricular tachycardia.Stressed out: the skeletal muscle ryanodine receptor as a target of stressNonspecific sarcolemmal cation channels are critical for the pathogenesis of malignant hyperthermia.Dantrolene-induced inhibition of skeletal L-type Ca2+ current requires RyR1 expression.Calcium signaling, excitability, and synaptic plasticity defects in a mouse model of Alzheimer's diseaseHalothane modulation of skeletal muscle ryanodine receptors: dependence on Ca2+, Mg2+, and ATP.Calpain activity and muscle wasting in sepsisDuchenne muscular dystrophy: an old anesthesia problem revisited.Role of endoplasmic reticulum Ca2+ signaling in the pathogenesis of Alzheimer disease
P2860
Q24644127-535F756F-5B91-4540-97C8-AD608C7BA70DQ24653442-9B3337D9-D326-479A-9371-F360C6394144Q24801946-742C33B0-874D-4009-A4AF-96F7E6A621F3Q26825721-59BF8A4C-1EFD-4D6B-8A24-0BFF27E56924Q28074804-914F4519-98EE-4C24-A823-BD9B05141D14Q28547114-B8FA829E-0266-4588-AE7F-711264946DFFQ28573445-53019BB6-35A5-44AA-8BEF-7A6DBBF9ED4CQ28575230-5609CCEE-E164-471E-80F8-3E7CA5A1D8C0Q29302167-C745FC0B-5F03-4FE2-AC94-C9B4A9E7CFF3Q30594530-459637B0-2956-4F73-B771-B58C1DEA186CQ30887483-4724290F-448D-47CB-A56F-BAE1CFA36AC0Q33719615-22E0C4D6-A33C-45AD-A0C8-2E4E56825B25Q33729288-AB6ADF71-1A7B-40F4-B1C8-78599185248CQ33755195-E1260EFE-4D8C-4219-88A8-1052F8C56D73Q33912937-64B98D15-FE53-4B2D-ABEA-93BC67177BABQ33988845-15258A55-C98F-4650-B67E-53D000B789E7Q33994773-E539C477-F6A7-4844-98ED-FD6CC22E0DF2Q34003214-1AAB0266-0D32-4B43-AE88-1F6E43A06117Q34063467-7FF5CF4A-8FDA-418F-9955-756B8B158F9DQ34194245-88EC2DAF-13A6-4378-B7AD-C2E75C4460C4Q34252541-6CA45959-A3F7-4909-A608-427650774B2CQ34306449-E9CF5868-04AE-436C-966E-2509B5B9A789Q34409630-75687AFA-D7FC-4961-8D06-FB36D57FE34FQ34709034-9A638DEE-1656-47BF-884F-65D8B0CBE0ACQ34719728-68D31827-0C93-471F-9463-8FD738D06AB3Q34752142-82A000CC-9B56-46FB-B5FA-7020D13582E6Q35250678-276DDBFB-9C08-4973-A0D5-A10297A01CB6Q35605391-A271F87D-7735-4A4B-A566-A0D1F48D6A3FQ35642611-299FB512-D9B1-4022-9956-63F66977799AQ35931379-BF6CA804-FDA3-4AA5-B623-C8DA47E63CEFQ36020105-3C1F1928-AE93-4284-BE4E-EE03CCA5FB03Q36037969-68971690-BEDE-41BA-8685-660B338A4AE5Q36407033-CE7AC247-647D-4DA5-B899-71DBA1A4822AQ36615166-7755F16A-794E-4AE7-B5B9-71B917A004D3Q36665389-A45D5EEF-E58D-40A1-80BA-D6261EE7171BQ36746166-C03DC4C5-2067-4E5F-B829-D9EE994418EDQ36768338-74459B0E-F757-43F3-8C86-B15ACF615A05Q36956035-A8E3FD17-90ED-4576-9941-CDEDF3E50C71Q37053906-672B4C6A-203E-4C1C-85A6-392E6461CAB4Q37180013-5092E5A1-C09B-4CF2-A9FE-93D5F45510B0
P2860
Dantrolene--a review of its pharmacology, therapeutic use and new developments.
description
2004 nî lūn-bûn
@nan
2004 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2004 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
name
Dantrolene--a review of its pharmacology, therapeutic use and new developments.
@ast
Dantrolene--a review of its pharmacology, therapeutic use and new developments.
@en
type
label
Dantrolene--a review of its pharmacology, therapeutic use and new developments.
@ast
Dantrolene--a review of its pharmacology, therapeutic use and new developments.
@en
prefLabel
Dantrolene--a review of its pharmacology, therapeutic use and new developments.
@ast
Dantrolene--a review of its pharmacology, therapeutic use and new developments.
@en
P2093
P1433
P1476
Dantrolene--a review of its pharmacology, therapeutic use and new developments.
@en
P2093
Gerbershagen MU
Weisshorn R
P304
P356
10.1111/J.1365-2044.2004.03658.X
P407
P577
2004-04-01T00:00:00Z